TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05239286
Drug: PVI dependant goal directed fluid therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the induction of anesthesia, Ringer solution infused at the dose of 2 ml/kg/h started as a basal rate of infusion. If the PVI was higher than 13% for more than 5 min, a 250-ml bolus of crystalloids administrated. If the PVI was still higher than 13% after the bolus, it was repeated every 5 min until the PVI was less than 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~In the cases where PVI was less than \< 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~Then the patient was turned to prone position and the same steps according to Massimo readings were repeated.
Study: NCT04941378
Drug: OTL38
Normalized name: Fluorodeoxyglucose F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time infusion of OTL38
Study: NCT06236841
Drug: XH-S004 tablet
Normalized name: TRENBOLONE ACETATE 200 mg / ESTRADIOL 20 mg SUBCUTANEOUS IMPLANT [Revalor XH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.
Study: NCT06236841
Drug: XH-S004 placebo tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
Study: NCT06194201
Drug: HRS9432
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing frequency: intravenously once week
Study: NCT05934799
Drug: Plavix® film-coated tablet 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.
Study: NCT04842721
Drug: Hypertonic Saturated Saline Mouth Rinse Active Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
Study: NCT05178953
Drug: Zinc Sulfate 220 mg Capsules
Normalized name: zinc sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
Study: NCT04860713
Drug: Nurtec (Rimegepant)
Normalized name: Nurtec
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 75 mg of ODT
Study: NCT04368806
Drug: JointStem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
Study: NCT04906889
Drug: Remifentanil Hydrochloride
Normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
Study: NCT05298033
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily vehicle ointment
Study: NCT05336968
Drug: Triamcinolone acetonide-Ketorolac-Ropivacaine
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
Study: NCT05710692
Drug: PRX-102 1 mg/kg every 2 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX-102 1 mg/kg every 2 weeks
Study: NCT05710692
Drug: PRX-102 2 mg/kg every 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX-102 2 mg/kg every 4 weeks
Study: NCT05288985
Drug: Systemic Analgesia Only Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic analgesia alone consists only of the 3 levels of analgesic treatment
Study: NCT04961801
Drug: Acalabrutinib, tacrolimus, methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Study: NCT06514469
Drug: Sufentanil intravenous administration based on paramedic competency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of sufentanil to patients with acute injury by paramedics based on their competencies
Study: NCT04991506
Drug: JS001
Normalized name: Janus Kinase Inhibitor JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
Study: NCT05756673
Drug: LISTERINE ZERO Alcohol Mouthwash COOL MINT
Normalized name: Listerine Mouthwash Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
Study: NCT05756673
Drug: LISTERINE COOL MINT Antiseptic Mouthwash
Normalized name: Listerine Cool Mint Antiseptic Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
Study: NCT06182072
Drug: ProAgio Dose Levels (DL) 1,2,3,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
Study: NCT06674096
Drug: RLC-CRCHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:~rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.~Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.~maintenance treatment period: chidamide d1,4,8,11
Study: NCT05362851
Drug: YYC301-1 & YYC301-2 & YYC301-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day
Study: NCT04933682
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT05362851
Drug: YYC301 placebo & Celecoxib 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator medication
Study: NCT05984381
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) orally
Study: NCT05984381
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 15 mg weekly
Study: NCT06184269
Drug: BR1017-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT05861258
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
Study: NCT06687174
Drug: MY008211A tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: MY008211A BID
Study: NCT06687174
Drug: MY008211A tablets matched placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MY008211A taken twice a day.
Study: NCT06721143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Infusion
Study: NCT04988087
Drug: MHV370
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHV370 for 24 weeks
Study: NCT06299514
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of heart failure therapies includes maximum tolerated doses of beta-blockers, aldosterone antagonists, ACE inhibitors, ARB, diuretics, ARNis
Study: NCT06721013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06719700
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.
Study: NCT06719700
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.
Study: NCT06224699
Drug: Toothpaste Product
Normalized name: Toothpaste Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of toothpaste with or without sodium carbonate at 67%
Study: NCT04885491
Drug: PDNO
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
Study: NCT06633055
Drug: JH013 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: JH013 injection is a BAFF-R inhibitor monoclonal antibody
Study: NCT06633055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: JH013 injections placebo
Study: NCT01003028
Drug: Remifentanil (Control) - Target Controlled Infusion system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use 20 ng/ml as max plasma concentration
Study: NCT04841499
Drug: BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: take 2 capsules orally each day for 7 days
Study: NCT05640713
Drug: ThisCART19A
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThisCART19A is a new type CAR-T therapy for patients with r/r B Cell Malignancy .
Study: NCT05640713
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT06552520
Drug: Placebo of TQH2722 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without drug substance
Study: NCT03992469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules made of cornstarch
Study: NCT06478758
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The ibuprofen group (n=36) was administered 800 mg of ibuprofen . All procedures were performed with the same team. During surgery, a 20% increase in the participant's heart rate and mean arterial pressure remifentanil infusion was administered. During the postoperative period, all participants continued to receive acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4. In the recovery room, the participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
Study: NCT06478758
Drug: Acetaminophen 100 MG/ML
Normalized name: acetaminophen 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators administered 1000 mg of acetaminophen to the participants in Group A. A 20% increase in the participant's heart rate and mean arterial pressure was evaluated as pain and remifentanil infusion was administered. All participants continued to receive the routine application of acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4, postoperatively.In the recovery room, participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
Study: NCT04906421
Drug: TVB-2640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, tablet
Study: NCT04752332
Drug: Standard Adjuvant ET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to label instructions.
Study: NCT04752332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05961592
Drug: R-2487
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic
Study: NCT06462586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules administered orally, once daily
Study: NCT06484530
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.
Study: NCT03766750
Drug: LIMA association
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 coated tablet, oral, once a day.
Study: NCT05874401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous placebo infusion
Study: NCT05360277
Drug: Tislelizumab + Capecitabine
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy.
Study: NCT05646303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and psychotherapy
Study: NCT05256277
Drug: CT101a
Approvals — FDA: no, EMA: no, PMDA: no
Description: cytokine-induced memory-like NK cells
Study: NCT06338553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule or tablet once before the pre-TZIELD® MMTT and once before one of the post-TZIELD® MMTTs.
Study: NCT05275777
Drug: ADG106
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
Study: NCT05275777
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as an intravenous infusion.
Study: NCT05275777
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as an intravenous infusion.
Study: NCT06342804
Drug: 4-MUST, 2 tablets, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets (256 mg), fasted
Study: NCT06342804
Drug: 4-MUST, 2 tablets, after meals
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets (256 mg), after meals
Study: NCT05883306
Drug: [14C]LXI-15028
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]LXI-15028
Study: NCT05794516
Drug: ZB004
Normalized name: Zoledronic acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ZB004 single doses administered subcutaneously as solution
Study: NCT05794516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single doses administered subcutaneously as solution
Study: NCT04510194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo; appearance and size are exact matching to the three study drugs.
Study: NCT06703658
Drug: Placebo(Part A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo oral on Day1
Study: NCT06703658
Drug: Placebo(Part B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as an oral tablet once daily.
Study: NCT05631327
Drug: JZP341
Approvals — FDA: no, EMA: no, PMDA: no
Description: JZP341 will be administered as a single, intravenous infusion over 2 hours.
Study: NCT06121557
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study: NCT06121557
Drug: Chemotherapeutic drug, ADC or PARP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
Study: NCT04453839
Drug: ZYESAMI (aviptadil acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
Study: NCT05416697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
Study: NCT05921006
Drug: RJ4287
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral，tablets，Once daily for 14 days
Study: NCT05921006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral，tablets，Once daily daily for 14 days
Study: NCT04746612
Drug: HH30134
Approvals — FDA: no, EMA: no, PMDA: no
Description: HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors
Study: NCT05952869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05517603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06512441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
Study: NCT05021536
Drug: AMX0035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary formulation of taurursodiol and sodium phenylbutyrate
Study: NCT04775797
Drug: AB-836
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules or Tablets
Study: NCT04775797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of Tablets
Study: NCT04775797
Drug: AB-836
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT04775797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT04775797
Drug: Nucleos(t)ide Analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT05723549
Drug: HCP1803-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period
Study: NCT05723549
Drug: RLD2002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period
Study: NCT05723549
Drug: HCP1904-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period
Study: NCT05746351
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a group will receive epidural Bupivacaine with fentanyl in normal labor
Study: NCT06232473
Drug: Benztropine Mesylate 0.5 MG and passive placebo RAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see arm description
Study: NCT05392127
Drug: SHR0302 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 Tablets once daily
Study: NCT04684550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
Study: NCT05835752
Drug: RAY1225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05835752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04446793
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
Study: NCT05699746
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
Study: NCT05804305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contained substance that has no therapeutic value.
Study: NCT04753203
Drug: Alpelisib plus Capecitabine combination
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation
Study: NCT05952856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06357806
Drug: NAs
Normalized name: DNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT05828238
Drug: [18F]SF-DEVD-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
Study: NCT05932511
Drug: 30% ascorbic acid in DMSO
Approvals — FDA: no, EMA: no, PMDA: no
Description: see above
Study: NCT05034484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT05404945
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 25mg/m2 IV
Study: NCT05508776
Drug: LEO 152020
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet~Route of administration: Orally~50 mg tablets
Study: NCT05508776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet~Route of administration: Orally~No active ingredient